Loading
Discussing and enrolling a patient in a trial takes an oncologist far longer than prescribing the usual treatment, and they are not paid for it. Paying for that time would remove a quiet disincentive.
Health systems and payers create a reimbursable code or protected-time allocation for trial discussion and enrolment (analogous to advance-care-planning codes), and sponsors' per-patient budgets include physician time explicitly rather than folding it into overhead. Academic promotion criteria count enrolment.
Shares Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Trials enrol too few, too slowly.
Shares American Society of Clinical Oncology (ASCO), Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Trials enrol too few, too slowly.
Shares Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Trials enrol too few, too slowly.
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.
Shares Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Incentives reward me-too drugs and marginal gains.
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.